我们有上千种药品(SKU)。但是,那些我们没有的品牌药和特药,原因是 PBM(药品福利管理机构)竭尽全力阻止药厂把这些药卖给我们。 他们知道,我们 15% 的加价率非常低,会让所有人开始质疑他们所收取的价格。 所以他们会告诉品牌药和特药的制造商,如果他们与 @costplusdrugs 合作,就会被调整处方目录的准入(formulary access)。 而这种调整可能让这些药厂损失数亿美元。 We have thousands of SKUs. But. The brand and specialty drugs we don’t have, are because the PBMs do all they can to prevent the manufacturers from selling to us. They know our markup of 15% is so low, it would make everyone question the prices they charge. So they tell brand and specialty med manufacturers, they will change their formulary access if they work with @costplusdrugs This could cause those manufacturers to lose hundreds of millions of dollars.

Mark CubanEntrepreneur & Investor

观点原文

我们有上千种药品(SKU)。但是,那些我们没有的品牌药和特药,原因是 PBM(药品福利管理机构)竭尽全力阻止药厂把这些药卖给我们。

他们知道,我们 15% 的加价率非常低,会让所有人开始质疑他们所收取的价格。

所以他们会告诉品牌药和特药的制造商,如果他们与 @costplusdrugs 合作,就会被调整处方目录的准入(formulary access)。

而这种调整可能让这些药厂损失数亿美元。

We have thousands of SKUs. But. The brand and specialty drugs we don’t have, are because the PBMs do all they can to prevent the manufacturers from selling to us.

They know our markup of 15% is so low, it would make everyone question the prices they charge.

So they tell brand and specialty med manufacturers, they will change their formulary access if they work with @costplusdrugs

This could cause those manufacturers to lose hundreds of millions of dollars.

Sharing

相关观点